Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel
OTCMKTS:BABYF

Else Nutrn 6/2/2025 Earnings Report

Else Nutrn logo
$0.03 +0.00 (+15.45%)
As of 03:34 PM Eastern
ProfileEarnings History

Else Nutrn EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Else Nutrn Revenue Results

Actual Revenue
$1.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Else Nutrn Announcement Details

Quarter
Date
6/2/2025
Time
During Market Hours
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Else Nutrn Earnings Headlines

Else Nutrition Commends Trump Administration's Expanded Commitment to Bolstering Infant Formulas Regulation in FY2027
April 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/else-nutrition-commends-trump-administrations-expanded-commitment-to-bolstering-infant-formulas-regulation-in-fy2027-302742255.html
Else Nutrition Holdings Inc.: Else Nutrition Expected to Benefit from FDA Regulatory Progress on Infant Formula Protein Standards
March 10, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/67901588-else-nutrition-holdings-inc-else-nutrition-expected-to-benefit-from-fda-regulatory-progress-on-infant-formula-protein-standards-008.htm
You’re Being LIED To About The Iran War
The mainstream explanation for the Iran airstrikes may not be the full story. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there's a deeper motive behind the bombing campaign that most coverage is ignoring. If you're making investment decisions based on what you're hearing in the news, Wiggin argues you could be working with an incomplete picture.tc pixel
May 5 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Else Nutrition Expected to Benefit from FDA Regulatory Progress on Infant Formula Protein Standards
March 10, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/else-nutrition-expected-to-benefit-from-fda-regulatory-progress-on-infant-formula-protein-standards-302708565.html
Else Nutrition Surpasses One Million Cans Sold Since Launch
January 29, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/else-nutrition-surpasses-one-million-cans-sold-since-launch-302673206.html
Else Nutrition Announces Results from Annual General Meeting of Shareholders
January 12, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/else-nutrition-announces-results-from-annual-general-meeting-of-shareholders-302659003.html
See More Else Nutrn Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Else Nutrn? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Else Nutrn and other key companies, straight to your email.

About Else Nutrn

Else Nutrition Holdings Inc is a plant-based infant and toddler nutrition company that develops dairy-free, soy-free and gluten-free formula powders under its flagship ELSE brand. The company’s core product line includes Stage 1 infant formula and Stage 3 toddler nutrition powders formulated with a proprietary blend of almond, buckwheat and tapioca ingredients designed to mimic the nutritional profile of traditional milk‐based formulas. These products are non-GMO and aim to address food sensitivities and allergen concerns in early childhood nutrition.

Founded in 2019 and headquartered in Tel Aviv, Israel, Else Nutrition began commercial sales in 2021 with initial distribution in Canada and Israel. Its manufacturing takes place in European Union-certified facilities, and products are sold through e-commerce channels as well as selected retail partners. Beyond Canada and Israel, Else Nutrition has entered into distribution partnerships in parts of Europe and is working toward regulatory approvals to support an expansion into the U.S. market.

Led by CEO Hadar Barshewitz-Attias and a management team with backgrounds in nutrition science and consumer packaged goods, Else Nutrition places a strong emphasis on research and development. The company is investing in clinical studies and regulatory compliance to support the safety and efficacy of its existing products, while also exploring the development of additional age-stage formulas and new delivery formats within the plant-based pediatric nutrition category.

View Else Nutrn Profile
Earnings Tools